Table 2

Baseline demographic and disease characteristics of patients receiving adalimumab+methotrexate in the ARMADA study

Mean (SD)*ARMADA (N=67)
Disease durationPrior DMARD treatment
≤5 years
n=51
>5–10 years
n=16
MTX+0–1
n=41
MTX+2
n=13
MTX+>2
n=13
Age, years55.2 (10.4)61.3 (13.6)55.5 (10.0)61.4 (14.6)55.6 (12.0)
Sex, female, n (%)38 (74.5)12 (75.0)32 (78.0)10 (76.9)8 (61.5)
RA duration, years3.6 (1.2)6.0 (0.0)3.9 (1.4)4.2 (1.7)4.9 (1.2)
Prior DMARD treatments†1.3 (1.2)2.1 (1.5)0.6 (0.5)2.0 (0.0)3.6 (1.0)
DAS28(CRP)5.7 (0.8)5.5 (0.9)5.8 (0.7)5.4 (0.9)5.5 (0.8)
SDAI40.1 (10.6)37.4 (11.2)41.5 (10.8)36.8 (10.4)35.7 (10.1)
HAQ-DI1.5 (0.6)1.6 (0.7)1.5 (0.5)1.3 (0.7)2.0 (0.4)
  • *Values are means (SD) unless specified otherwise.

  • †Including methotrexate.

  • DAS28(CRP), 28-joint Disease Activity Score based on C-reactive protein; DMARD, disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; RA, rheumatoid arthritis; SDAI, Simplified Disease Activity Index.